Dergiler / Klinik Psikofarmakoloji Bülteni / 2016 / Cilt: 26 - Sayı: 2

Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting

Sayfa
126–133
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Maternal self-reported antisocial and anxiety/depressive symptomatology were statistically significantly associated with worse response to treatment in terms of CPRS (respectively, OR=0.83, 95% CI: 0.75-0.92, p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: To investigate the effect of Attention Deficit Hyperactivity Disorder (ADHD), antisocial behavior and anxiety/depression ratings of mothers, and child and adolescents' age, gender, ADHD subtype, and comorbidity on one-month drug treatment response to OROS methylphenidate in ADHD in a naturalistic setting.
📊
Temel Bulgular & Veri:Methods: The analyses included 223 subjects (191 boys, 32 girls; age 6-15 years, mean: 9.4) treated with OROS methylphenidate (18-72 mg/day, mean: 31 mg/d; 0.4-1.4 mg/kg/d) for one-month.
💡
Sonuç & Katkı:Maternal self-reported antisocial and anxiety/depressive symptomatology were statistically significantly associated with worse response to treatment in terms of CPRS (respectively, OR=0.83, 95% CI: 0.75-0.92, p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: To investigate the effect of Attention Deficit Hyperactivity Disorder (ADHD), antisocial behavior and anxiety/depression ratings of mothers, and child and adolescents' age, gender, ADHD subtype, and comorbidity on one-month drug treatment response to OROS methylphenidate in ADHD in a naturalistic setting. Methods: The analyses included 223 subjects (191 boys, 32 girls; age 6-15 years, mean: 9.4) treated with OROS methylphenidate (18-72 mg/day, mean: 31 mg/d; 0.4-1.4 mg/kg/d) for one-month. Treatment response was defined as larger than 25% or more decrease in pre-treatment the Conners Parent Rating Scale (CPRS) or the Conners Teacher Rating Scale (CTRS) total scores and the Clinical Global Impression improvement with drug treatment 3 (minimally improved) or higher. Maternal ADHD, antisocial behavior and anxiety/ depression ratings were obtained by the Adult Self Rating (ASR). Logistic regression analyses were computed in order to calculate the effects of gender; age; ADHD subtype; comorbid anxiety disorder, learning disorder, oppositional defiant/conduct disorder; maternal ASR Anxiety/Depression, ADHD and Antisocial scores. Results: 35.2% of subjects had statistically significant 25% or more decrease in pretreatment CPRS total scores and 38.6% of subjects had statistically significant 25% or more decrease in pretreatment CTRS total scores. The subjects with comorbid anxiety disorder had the poorest drug response. Maternal self-reported antisocial and anxiety/depressive symptomatology were statistically significantly associated with worse response to treatment in terms of CPRS (respectively, OR=0.83, 95% CI: 0.75-0.92, p

🔖

Bu Makaleye Atıf Yap

ÇÖP, E., ONER, O., YURTBASİ, P., MUNİR, K. (2022). Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting. Klinik Psikofarmakoloji Bülteni, Cilt: 26 - Sayı: 2, 126–133. https://ajindex.com/articles/573917

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Swanson JM, Gupta S, Williams L, Agler D, Lerner M, Wigal S. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 2002
  2. 41(11):1306-14. [CrossRef] 2. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention deficit/hyperactivity disorder. Pediatrics 2001
  3. 108(4):883- 92. [CrossRef] 3. Yildiz-OC O, Agaoglu B, Karakaya I, Sismanlar SG, CakinMemik N. Efficiency and tolerability of OROSmethylphenidate in Turkish children and adolescents with attention-deficit/hyperactivity disorder. Anatolian Journal of Psychiatry 2010
  4. (Turkish) 4. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled, effectiveness trial of OROSmethylphenidate compared to usual care with immediaterelease methylphenidate in attention deficit- hyperactivity disorder. Can J Clin Pharmacol 2006
  5. 13(1):e50-62. 5. Akyol-Ardic U, Ercan ES, Ercan E, Yuce D, Kabukcu-Basay B. Osmotic release oral system methylphenidate is more effective than immediate release methylphenidate: a retrospective chart review in Turkish children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2014
  6. 24(4):342-9. [CrossRef] 6. Owens EB, Hinshaw SP, Kraemer HC, Arnold LE, Abikoff HB, Cantwell DP, et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol 2003
  7. 71(3):540 -52. [CrossRef] 7. Alsen S, Resmi H, Ozek H, Tufan AE, Bulbul M, Pekcanlar AA. Plasma norepinephrine and dopamine levels in prepubertal male children with attention-deficit hyperactivity disorder do not change with 8 weeks of methylphenidate treatment Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2015
  8. 25(3):259- 66. [CrossRef] 8. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 2003
  9. 112(5):e404. [CrossRef] 9. Gorman EB, Klorman R, Thatcher JE, Borgstedt AD. Effects of methylphenidate on subtypes of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006
  10. 45(7):808-16. [CrossRef] 10. Solanto M, Newcorn J, Vail L, Gilbert S, Ivanov I, Lara R. Stimulant drug response in the pre